Santhera Pharmaceuticals Holding AG (SW:SANN) — Market Cap & Net Worth
Market Cap & Net Worth: Santhera Pharmaceuticals Holding AG (SANN)
Santhera Pharmaceuticals Holding AG (SW:SANN) has a market capitalization of $243.45 Million (CHF192.56 Million) as of August 4, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #15687 globally and #170 in its home market, demonstrating a -4.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Santhera Pharmaceuticals Holding AG's stock price CHF14.16 by its total outstanding shares 14220173 (14.22 Million). See how much does Santhera Pharmaceuticals Holding AG reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Santhera Pharmaceuticals Holding AG Market Cap History: 2015 to 2026
Santhera Pharmaceuticals Holding AG's market capitalization history from 2015 to 2026. Data shows change from $16.13 Billion to $254.57 Million (-32.70% CAGR).
Santhera Pharmaceuticals Holding AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Santhera Pharmaceuticals Holding AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.93x
Santhera Pharmaceuticals Holding AG's market cap is 2.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.53 Billion | $19.03 Million | -$35.41 Million | 500.63x | N/A |
| 2017 | $6.46 Billion | $22.94 Million | -$51.53 Million | 281.70x | N/A |
| 2018 | $1.21 Billion | $31.66 Million | -$54.19 Million | 38.28x | N/A |
| 2019 | $2.04 Billion | $75.38 Million | -$18.97 Million | 27.05x | N/A |
| 2020 | $503.39 Million | $15.01 Million | -$67.66 Million | 33.54x | N/A |
| 2021 | $239.11 Million | $-1.59 Million | -$55.53 Million | -149.91x | N/A |
| 2022 | $248.10 Million | $7.47 Million | -$71.08 Million | 33.20x | N/A |
| 2023 | $176.37 Million | $103.41 Million | $54.78 Million | 1.71x | 3.22x |
| 2024 | $248.46 Million | $39.12 Million | -$41.97 Million | 6.35x | N/A |
| 2025 | $226.52 Million | $77.19 Million | -$49.24 Million | 2.93x | N/A |
Competitor Companies of SANN by Market Capitalization
Companies near Santhera Pharmaceuticals Holding AG in the global market cap rankings as of August 4, 2026.
Key companies related to Santhera Pharmaceuticals Holding AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Santhera Pharmaceuticals Holding AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Santhera Pharmaceuticals Holding AG's market cap moved from $16.13 Billion to $ 254.57 Million, with a yearly change of -32.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF254.57 Million | +12.38% |
| 2025 | CHF226.52 Million | -8.83% |
| 2024 | CHF248.46 Million | +40.88% |
| 2023 | CHF176.37 Million | -28.91% |
| 2022 | CHF248.10 Million | +3.76% |
| 2021 | CHF239.11 Million | -52.50% |
| 2020 | CHF503.39 Million | -75.31% |
| 2019 | CHF2.04 Billion | +68.25% |
| 2018 | CHF1.21 Billion | -81.25% |
| 2017 | CHF6.46 Billion | -32.17% |
| 2016 | CHF9.53 Billion | -40.91% |
| 2015 | CHF16.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Santhera Pharmaceuticals Holding AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $243.45 Million USD |
| MoneyControl | $243.45 Million USD |
| MarketWatch | $243.45 Million USD |
| marketcap.company | $243.45 Million USD |
| Reuters | $243.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more